These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 15494421)

  • 1. Polyclonal chemoprotection against temozolomide in a large-animal model of drug resistance gene therapy.
    Neff T; Beard BC; Peterson LJ; Anandakumar P; Thompson J; Kiem HP
    Blood; 2005 Feb; 105(3):997-1002. PubMed ID: 15494421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo selection of hematopoietic progenitor cells and temozolomide dose intensification in rhesus macaques through lentiviral transduction with a drug resistance gene.
    Larochelle A; Choi U; Shou Y; Naumann N; Loktionova NA; Clevenger JR; Krouse A; Metzger M; Donahue RE; Kang E; Stewart C; Persons D; Malech HL; Dunbar CE; Sorrentino BP
    J Clin Invest; 2009 Jul; 119(7):1952-63. PubMed ID: 19509470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoprotection of human hematopoietic stem cells by simultaneous lentiviral overexpression of multidrug resistance 1 and O(6)-methylguanine-DNA methyltransferase(P140K).
    Maier P; Spier I; Laufs S; Veldwijk MR; Fruehauf S; Wenz F; Zeller WJ
    Gene Ther; 2010 Mar; 17(3):389-99. PubMed ID: 19865182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The P140K mutant of human O(6)-methylguanine-DNA-methyltransferase (MGMT) confers resistance in vitro and in vivo to temozolomide in combination with the novel MGMT inactivator O(6)-(4-bromothenyl)guanine.
    Woolford LB; Southgate TD; Margison GP; Milsom MD; Fairbairn LJ
    J Gene Med; 2006 Jan; 8(1):29-34. PubMed ID: 16075413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo selection of autologous MGMT gene-modified cells following reduced-intensity conditioning with BCNU and temozolomide in the dog model.
    Gori JL; Beard BC; Ironside C; Karponi G; Kiem HP
    Cancer Gene Ther; 2012 Aug; 19(8):523-9. PubMed ID: 22627392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential competitive resistance to methylating versus chloroethylating agents among five O6-alkylguanine DNA alkyltransferases in human hematopoietic cells.
    Fontes AM; Davis BM; Encell LP; Lingas K; Covas DT; Zago MA; Loeb LA; Pegg AE; Gerson SL
    Mol Cancer Ther; 2006 Jan; 5(1):121-8. PubMed ID: 16432170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hematoprotection and enrichment of transduced cells in vivo after gene transfer of MGMT(P140K) into hematopoietic stem cells.
    Jansen M; Sorg UR; Ragg S; Flasshove M; Seeber S; Williams DA; Moritz T
    Cancer Gene Ther; 2002 Sep; 9(9):737-46. PubMed ID: 12189523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hematopoietic expression of O(6)-methylguanine DNA methyltransferase-P140K allows intensive treatment of human glioma xenografts with combination O(6)-benzylguanine and 1,3-bis-(2-chloroethyl)-1-nitrosourea.
    Kreklau EL; Pollok KE; Bailey BJ; Liu N; Hartwell JR; Williams DA; Erickson LC
    Mol Cancer Ther; 2003 Dec; 2(12):1321-9. PubMed ID: 14707273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. F2A sequence linking MGMT(P140K) and MDR1 in a bicistronic lentiviral vector enables efficient chemoprotection of haematopoietic stem cells.
    Maier P; Heckmann D; Spier I; Laufs S; Zucknick M; Allgayer H; Fruehauf S; Zeller WJ; Wenz F
    Cancer Gene Ther; 2012 Nov; 19(11):802-10. PubMed ID: 23037811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection and in vivo selection of hematopoietic stem cells using temozolomide, O6-benzylguanine, and an alkyltransferase-expressing retroviral vector.
    Sawai N; Zhou S; Vanin EF; Houghton P; Brent TP; Sorrentino BP
    Mol Ther; 2001 Jan; 3(1):78-87. PubMed ID: 11162314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitochondrial targeting of human O6-methylguanine DNA methyltransferase protects against cell killing by chemotherapeutic alkylating agents.
    Cai S; Xu Y; Cooper RJ; Ferkowicz MJ; Hartwell JR; Pollok KE; Kelley MR
    Cancer Res; 2005 Apr; 65(8):3319-27. PubMed ID: 15833865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterisation of a P140K mutant O6-methylguanine-DNA-methyltransferase (MGMT)-expressing transgenic mouse line with drug-selectable bone marrow.
    Kramer BA; Lemckert FA; Alexander IE; Gunning PW; McCowage GB
    J Gene Med; 2006 Sep; 8(9):1071-85. PubMed ID: 16927363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitization of pancreatic tumor xenografts to carmustine and temozolomide by inactivation of their O6-Methylguanine-DNA methyltransferase with O6-benzylguanine or O6-benzyl-2'-deoxyguanosine.
    Kokkinakis DM; Ahmed MM; Chendil D; Moschel RC; Pegg AE
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3801-7. PubMed ID: 14506174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloablation is not required to select and maintain expression of the drug-resistance gene, mutant MGMT, in primary and secondary recipients.
    Bowman JE; Reese JS; Lingas KT; Gerson SL
    Mol Ther; 2003 Jul; 8(1):42-50. PubMed ID: 12842427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo selection and chemoprotection after drug resistance gene therapy in a nonmyeloablative allogeneic transplantation setting in dogs.
    Gerull S; Beard BC; Peterson LJ; Neff T; Kiem HP
    Hum Gene Ther; 2007 May; 18(5):451-6. PubMed ID: 17536975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells.
    Ragg S; Xu-Welliver M; Bailey J; D'Souza M; Cooper R; Chandra S; Seshadri R; Pegg AE; Williams DA
    Cancer Res; 2000 Sep; 60(18):5187-95. PubMed ID: 11016647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the P140K, PVP(138-140)MLK, and G156A O6-methylguanine-DNA methyltransferase mutants: implications for drug resistance gene therapy.
    Davis BM; Roth JC; Liu L; Xu-Welliver M; Pegg AE; Gerson SL
    Hum Gene Ther; 1999 Nov; 10(17):2769-78. PubMed ID: 10584923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. O6-methylguanine-DNA methyltransferase, O6-benzylguanine, and resistance to clinical alkylators in pediatric primary brain tumor cell lines.
    Bobola MS; Silber JR; Ellenbogen RG; Geyer JR; Blank A; Goff RD
    Clin Cancer Res; 2005 Apr; 11(7):2747-55. PubMed ID: 15814657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lentiviral transduction of P140K MGMT into human CD34(+) hematopoietic progenitors at low multiplicity of infection confers significant resistance to BG/BCNU and allows selection in vitro.
    Zielske SP; Gerson SL
    Mol Ther; 2002 Apr; 5(4):381-7. PubMed ID: 11945064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reciprocal relationship between O6-methylguanine-DNA methyltransferase P140K expression level and chemoprotection of hematopoietic stem cells.
    Milsom MD; Jerabek-Willemsen M; Harris CE; Schambach A; Broun E; Bailey J; Jansen M; Schleimer D; Nattamai K; Wilhelm J; Watson A; Geiger H; Margison GP; Moritz T; Baum C; Thomale J; Williams DA
    Cancer Res; 2008 Aug; 68(15):6171-80. PubMed ID: 18676840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.